london euretina
retina race

Dexamethasone intravitreal implant in thirty patients with diabetic macular edema: thirty-one months of follow-up

Session Details

Session Title: New Drug Treatment and Technology I

Session Date/Time: Friday 18/09/2015 | 11:00-12:30

Paper Time: 12:20

Venue: Thalie.

First Author: : P.Busatto ITALY

Co Author(s): :    G. Beltrame              

Abstract Details

PURPOSE:To evaluate the efficacy and safety of dexamethasone intravitreal implant (Ozurdex, DEX 0.7 mg) in the treatment of patients with diabetic macular edema

Setting:

Department of Ophthalmology Civil Hospital S. Maria degli Angeli Pordenone Italy

Methods:

Thirty patients with diabetic macular oedema with central retinal thickness > 300 µ were treated with dexamethazone slow release intra-vitreal implant and followed for 31 months. Mean pre op best-corrected visual acuity was of 20/80 ( from 20/200 to 20/32 Snellen equivalent), and mean central retinal thickness (CRT) was of 536 μm ( from 325 to 990 μm) by optical coherence tomography. Retreatment criteria , if eligible , was no more often than every 6 months

Results:

Mean BCVA from baseline at study end was 20/50. The percentage of patients with ≥15-letter improvement in BCVA from baseline at study end was 28.6 %. Mean number of treatments received over 31 months was 4.6, (1 DEX every 8,6 months). Mean average reduction in CRT from baseline was (-228, 5 μm). Phakic eyes developed cataract in 80.9 % of cases. Intaocular pressure increase, when present, was well controlled by topical eye drops . No surgery was necessary.

Conclusions:

The DEX implant is a safe and effective device in improving BCVA in diabetic patients with macular edema

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy